At a glance
- Originator Aventis
- Class Radioprotectives
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Radiation injuries
Most Recent Events
- 10 Oct 1996 No-Development-Reported for Radiation injuries/Radioprotection in USA (Unknown route)
- 02 May 1995 Preclinical development for Radiation injuries/Radioprotection in USA (Unknown route)